Boehringer joins consortium to develop new cystic fibrosis gene therapies
Collaboration also includes UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, and Oxford BioMedica
Read More
Author: George Underwood
EMA grants PRIME status for Roche Huntington’s drug
RG6042 could be the first therapy targeting the underlying cause of the disease
Read More
EMA grants PRIME status for Roche Huntington’s drug
RG6042 could be the first therapy targeting the underlying cause of the disease
Read More
AZ and MSD get orphan designation for neurofibromatosis drug
Selumetinib is a MEK 1/2 inhibitor for the rare disease
Read More
Almirall buys Allergan’s US dermatology portfolio for $650 million
The deal comprises the brands Aczone, Tazorac, Azelex, Cordran Tape and SeysaraTM
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
